20 results
8-K
EX-99.1
TRML
Tourmaline Bio Inc
24 Jan 24
Results of Operations and Financial Condition
5:10pm
lesions. Beyond providing protection, the immune system regulates key regenerative and homeostatic processes in healthy individuals on an ongoing basis
DEF 14A
54nrcar0oyam01gkn6t
29 Apr 22
Definitive proxy
4:24pm
10-K
mem65o3oe7xew6 7yow
17 Mar 22
Annual report
4:31pm
8-K
EX-99.1
ke9oadvk
2 Nov 21
Talaris Therapeutics Announces Initiation of Phase 2 Clinical Trial of FCR001 in Delayed Tolerance Induction
4:02pm
8-K
EX-99.1
gun4guia7 o9h
12 Aug 21
Talaris Therapeutics Announces Second Quarter 2021 Financial Results and Provides Business Update
10:35am
10-Q
ksa9arwvpn40n
14 Jun 21
Quarterly report
4:21pm
8-K
EX-99.1
qkj zfkuoz7e1b08ngrr
14 Jun 21
Talaris Therapeutics Announces First Quarter 2021 Financial Results and Provides Business
4:07pm
424B4
ym3yapaf8vlnbj7s
10 May 21
Prospectus supplement with pricing info
4:20pm
S-1/A
4z7dej0xf6
3 May 21
IPO registration (amended)
6:07am
S-1
tp4j4bwctasccprjv2
16 Apr 21
IPO registration
5:03pm
DRS/A
6lbsbsmmmx43vrbm6qae
1 Apr 21
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next